FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen in the Treatment of Pain and Inflammation – YAHOO!

FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and safety in the management of acute and chronic …